XML 27 R2.htm IDEA: XBRL DOCUMENT
v3.25.1

Pay vs Performance Disclosure - USD ($) | 12 Months Ended
--- | ---
Dec. 31, 2024 | Dec. 31, 2023 | Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Pay vs Performance Disclosure |  |  |  |  |
Pay vs Performance Disclosure, Table | Pay Versus Performance Disclosure In accordance with rules adopted by the SEC pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, we provide the following disclosure regarding executive “Compensation Actually Paid” (“CAP”) and certain performance measures for the fiscal years listed below. The Compensation Discussion & Analysis (“CD&A”) describes the compensation setting process for our executive officers, which is done independently from the disclosure requirements. Pay Versus Performance The following table provides the information required for our NEOs for each of the fiscal years ended December 31, 2024, December 31, 2023, December 31, 2022, December 31, 2021, and December 31, 2020 along with the required financial information required for each fiscal year. CAP is calculated in accordance with SEC rules and includes the increase or decrease in value of certain elements of compensation over each fiscal year, including compensation granted in a prior year. CAP does not correlate to the total amount of cash or equity compensation paid or received during each fiscal year. The calculations do not reflect the actual sale of stock underlying equity awards or the exercise of stock options by the executive, and the amount of compensation ultimately received may, in fact, be different from the CAP amounts disclosed in the table below:
|  |  |  |  |  |  |  |  |  | Value of Initial Fixed $100 Investment Based On: |  |  |  |
Year (1)(2) |  | Summary Compensation Table Total for PEO (3) |  | Compensation Actually Paid to PEO (3)(4)(5) |  | Average Summary Compensation Table Total for Non-PEO NEOs (3) |  | Average Compensation Actually Paid to Non-PEO NEOs (3)(4)(5) |  | Total Shareholder Return (6) |  | Peer Group Total Shareholder Return (7) |  | Net Income (Loss) (in millions) (8) |  | Revenue (in millions) (9)
|  | $ |  | $ |  | $ |  | $ |  | $ |  | $ |  | $ |  | $
2024 |  |  |  | 8,199,136 |  |  |  |  | 9,626,783 |  |  |  |  | 2,983,724 |  |  |  |  | 2,398,150 |  |  |  |  | 327.99 |  |  |  |  | 105.42 |  |  |  |  | 35.5 |  |  |  |  | 441.5 |
2023 |  |  |  | 6,758,070 |  |  |  |  | 12,840,614 |  |  |  |  | 2,493,824 |  |  |  |  | 3,227,811 |  |  |  |  | 415.20 |  |  |  |  | 106.34 |  |  |  |  | (25.0 | ) |  |  |  | 241.6 |
2022 |  |  |  | 3,287,862 |  |  |  |  | 25,221,314 |  |  |  |  | 958,883 |  |  |  |  | 4,539,310 |  |  |  |  | 324.67 |  |  |  |  | 99.81 |  |  |  |  | (36.2 | ) |  |  |  | 93.5 |
2021 |  |  |  | 7,370,365 |  |  |  |  | 5,172,952 |  |  |  |  | 1,441,564 |  |  |  |  | 1,070,395 |  |  |  |  | 100.79 |  |  |  |  | 125.43 |  |  |  |  | (44.2 | ) |  |  |  | 30.3 |
2020 |  |  |  | 2,385,687 |  |  |  |  | 2,664,897 |  |  |  |  | 928,500 |  |  |  |  | 1,040,808 |  |  |  |  | 104.68 |  |  |  |  | 130.04 |  |  |  |  | (28.7 | ) |  |  |  | 25.6 |
(1) | For all years reported, the principal executive officer (“PEO”) was Waleed H. Hassanein, M.D.
(2) | Non-PEO NEOs reflect the following executives for each covered fiscal year:
2024: Gerardo Hernandez, Tamer Khayal, M.D., Nicholas Corcoran, Anil Ranganath, Stephen Gordon; 2023: Stephen Gordon, Tamer Khayal, M.D., Nicholas Corcoran, Anil Ranganath; 2022: Stephen Gordon, Tamer Khayal, M.D., Miriam Provost, Laura Damme; 2021: Stephen Gordon, Tamer Khayal, M.D., Miriam Provost, Laura Damme; and 2020: Stephen Gordon, Tamer Khayal, M.D.
(3) | Deductions from, and additions to, total compensation in the Summary Compensation Table by year to calculate CAP are shown in the tables below. The amounts reflected for fiscal year 2023 have been revised from the amounts previously reported in last year’s Proxy Statement to reflect the correct Average Summary Compensation Table Total for our Non-PEO NEOs and to incorporate an inadvertent omission of certain tranches of outstanding stock option awards granted in a previous year that remained outstanding as of the end of fiscal year 2023.
|  | CAP to PEO |
|  | 2024 |  |  | 2023 |  |  | 2022 |  |  | 2021 |  |  | 2020 |
|  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |
Summary Compensation Table Total |  |  | 8,199,136 |  |  |  | 6,758,070 |  |  |  | 3,287,862 |  |  |  | 7,370,365 |  |  |  | 2,385,687 |
Adjustments for Stock and Option Awards |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment for grant date fair values in the Summary Compensation Table |  |  | (6,096,424 | ) |  |  | (4,940,574 | ) |  |  | (1,825,900 | ) |  |  | (6,377,940 | ) |  |  | (1,445,960 | )
Year-end fair value of unvested awards granted in the covered fiscal year |  |  | 3,958,387 |  |  |  | 5,365,601 |  |  |  | 10,641,357 |  |  |  | 2,075,714 |  |  |  | 1,671,287 |
Year-over-year difference of year-end fair values for unvested awards granted in prior years that remained outstanding at the covered fiscal year end |  |  | (2,382,164 | ) |  |  | 3,440,246 |  |  |  | 8,789,191 |  |  |  | (136,012 | ) |  |  | 67,306 |
Fair values at vest date for awards granted and vested in covered fiscal year |  |  | 971,689 |  |  |  | 532,735 |  |  |  | 1,647,831 |  |  |  | 949,688 |  |  |  | 312,077 |
Difference in fair values between prior year-end fair values and vest date fair values for awards granted in prior years and vesting in the covered fiscal year |  |  | 4,976,159 |  |  |  | 1,684,536 |  |  |  | 2,680,973 |  |  |  | 1,291,136 |  |  |  | (325,501 | )
Compensation Actually Paid (as calculated) |  |  | 9,626,783 |  |  |  | 12,840,614 |  |  |  | 25,221,314 |  |  |  | 5,172,952 |  |  |  | 2,664,897 |
|  | Average CAP to Non-PEO NEOs |
|  | 2024 |  |  | 2023 |  |  | 2022 |  |  | 2021 |  |  | 2020 |
|  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |
Summary Compensation Table Total |  |  | 2,983,724 |  |  |  | 2,493,824 |  |  |  | 958,883 |  |  |  | 1,441,564 |  |  |  | 928,500 |
Adjustments for Stock and Option Awards |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment for grant date fair values in the Summary Compensation Table |  |  | (2,053,545 | ) |  |  | (1,738,234 | ) |  |  | (328,662 | ) |  |  | (977,265 | ) |  |  | (405,485 | )
Year-end fair value of unvested awards granted in the covered fiscal year |  |  | 1,079,261 |  |  |  | 1,822,445 |  |  |  | 1,915,468 |  |  |  | 318,056 |  |  |  | 469,469 |
Year-over-year difference of year-end fair values for unvested awards granted in prior years that remained outstanding at the covered fiscal year end |  |  | (371,623 | ) |  |  | 372,583 |  |  |  | 1,344,256 |  |  |  | (16,871 | ) |  |  | 9,332 |
Fair values at vest date for awards granted and vested in covered fiscal year |  |  | 188,739 |  |  |  | 93,271 |  |  |  | 296,601 |  |  |  | 145,504 |  |  |  | 87,658 |
Difference in fair values between prior year-end fair values and vest date fair values for awards granted in prior years and vesting in the covered fiscal year |  |  | 571,594 |  |  |  | 183,922 |  |  |  | 352,765 |  |  |  | 159,408 |  |  |  | (48,666 | )
Compensation Actually Paid (as calculated) |  |  | 2,398,150 |  |  |  | 3,227,811 |  |  |  | 4,539,310 |  |  |  | 1,070,395 |  |  |  | 1,040,808 |
(4) | The valuation of RSU awards included as part of CAP was based on the grant date closing price and the closing price on the applicable vesting date or fiscal year end. The following summarizes the valuation assumptions used for stock option awards included as part of CAP:
| a. | Expected life of each stock option is based on the “simplified method” using an average of the remaining vesting period and remaining term, as of the applicable vesting date or fiscal year end.
| b. | The exercise price is based on each grant date closing price and fair value is based on the closing price on the applicable vesting date or fiscal year end.
| c. | Risk free rate is based on the Treasury Constant Maturity rate closest to the remaining expected life as of the applicable vesting date or fiscal year end.
| d. | Historical volatility is based on the daily price history for each year of remaining expected life prior to each applicable vesting date or fiscal year end; closing prices are provided by S&P Capital IQ and are adjusted for dividends and splits.
| e. | Annual dividend yield on each applicable vesting date or fiscal year end is assumed to be zero.
(5) | The following table illustrates the valuation assumptions as of the vesting date for stock options that vested in each of the covered fiscal years:
|  | For Stock Options Vesting in
|  | 2024 |  | 2023 |  | 2022 |  | 2021 |  | 2020
Expected volatility |  | 72.02% - 77.95% |  | 71.79% - 77.78% |  | 69.15% - 76.30% |  | 64.38% - 72.22% |  | 56.71% - 71.56%
Expected dividend yield |  | 0.00% |  | 0.00% |  | 0.00% |  | 0.00% |  | 0.00%
Expected term, in years |  | 3.0 - 5.0 |  | 3.0 - 5.0 |  | 3.2 - 5.0 |  | 3.0 - 5.0 |  | 3.2 - 5.0
Risk-free interest rate |  | 3.44% - 4.81% |  | 3.54% - 4.91% |  | 0.97% - 4.48% |  | 0.19% - 1.34% |  | 0.15% - 1.69%
(6) | The amounts reported in this column represent the cumulative total return on $100 invested in the Company’s common stock as of December 31, 2019 through the last trading day for the applicable fiscal year in the table. The Company has not paid any dividends since its IPO.
(7) | The amounts reported in this column represent the weighted cumulative total return on $100 invested as of December 31, 2019 through the last trading day for the applicable fiscal year in the table, weighted according to the respective companies’ stock market capitalization at the beginning of each period for which a return is indicated. The peer group total shareholder return set forth in this table utilizes the Nasdaq Healthcare Index (IXHC), which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report on Form 10-K for the year ended December 31, 2024. The return of this index is calculated assuming reinvestment of dividends during the period presented.
(8) | The amounts reported in this column represent the amount of net income (loss) reflected in the Company’s audited financial statements for the applicable year.
(9) | The amounts reported in this column represent revenue, our Company-Selected Measure, which we believe is the most important financial measure used to link compensation actually paid to our named executive officers to Company performance for 2024. The amounts represent the amount of revenue reflected in the Company’s audited financial statements for the applicable year.
Company Selected Measure Name | Revenue |  |  |  |
Named Executive Officers, Footnote |
(2) | Non-PEO NEOs reflect the following executives for each covered fiscal year:
2024: Gerardo Hernandez, Tamer Khayal, M.D., Nicholas Corcoran, Anil Ranganath, Stephen Gordon; 2023: Stephen Gordon, Tamer Khayal, M.D., Nicholas Corcoran, Anil Ranganath; 2022: Stephen Gordon, Tamer Khayal, M.D., Miriam Provost, Laura Damme; 2021: Stephen Gordon, Tamer Khayal, M.D., Miriam Provost, Laura Damme; and 2020: Stephen Gordon, Tamer Khayal, M.D. |  |  |  |
Peer Group Issuers, Footnote | The peer group total shareholder return set forth in this table utilizes the Nasdaq Healthcare Index (IXHC), which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report on Form 10-K for the year ended December 31, 2024. The return of this index is calculated assuming reinvestment of dividends during the period presented. |  |  |  |
PEO Total Compensation Amount | $ 8,199,136 | $ 6,758,070 | $ 3,287,862 | $ 7,370,365 | $ 2,385,687
PEO Actually Paid Compensation Amount | $ 9,626,783 | 12,840,614 | 25,221,314 | 5,172,952 | 2,664,897
Adjustment To PEO Compensation, Footnote |
(3) | Deductions from, and additions to, total compensation in the Summary Compensation Table by year to calculate CAP are shown in the tables below. The amounts reflected for fiscal year 2023 have been revised from the amounts previously reported in last year’s Proxy Statement to reflect the correct Average Summary Compensation Table Total for our Non-PEO NEOs and to incorporate an inadvertent omission of certain tranches of outstanding stock option awards granted in a previous year that remained outstanding as of the end of fiscal year 2023.
|  | CAP to PEO |
|  | 2024 |  |  | 2023 |  |  | 2022 |  |  | 2021 |  |  | 2020 |
|  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |
Summary Compensation Table Total |  |  | 8,199,136 |  |  |  | 6,758,070 |  |  |  | 3,287,862 |  |  |  | 7,370,365 |  |  |  | 2,385,687 |
Adjustments for Stock and Option Awards |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment for grant date fair values in the Summary Compensation Table |  |  | (6,096,424 | ) |  |  | (4,940,574 | ) |  |  | (1,825,900 | ) |  |  | (6,377,940 | ) |  |  | (1,445,960 | )
Year-end fair value of unvested awards granted in the covered fiscal year |  |  | 3,958,387 |  |  |  | 5,365,601 |  |  |  | 10,641,357 |  |  |  | 2,075,714 |  |  |  | 1,671,287 |
Year-over-year difference of year-end fair values for unvested awards granted in prior years that remained outstanding at the covered fiscal year end |  |  | (2,382,164 | ) |  |  | 3,440,246 |  |  |  | 8,789,191 |  |  |  | (136,012 | ) |  |  | 67,306 |
Fair values at vest date for awards granted and vested in covered fiscal year |  |  | 971,689 |  |  |  | 532,735 |  |  |  | 1,647,831 |  |  |  | 949,688 |  |  |  | 312,077 |
Difference in fair values between prior year-end fair values and vest date fair values for awards granted in prior years and vesting in the covered fiscal year |  |  | 4,976,159 |  |  |  | 1,684,536 |  |  |  | 2,680,973 |  |  |  | 1,291,136 |  |  |  | (325,501 | )
Compensation Actually Paid (as calculated) |  |  | 9,626,783 |  |  |  | 12,840,614 |  |  |  | 25,221,314 |  |  |  | 5,172,952 |  |  |  | 2,664,897 |
Non-PEO NEO Average Total Compensation Amount | $ 2,983,724 | 2,493,824 | 958,883 | 1,441,564 | 928,500
Non-PEO NEO Average Compensation Actually Paid Amount | $ 2,398,150 | 3,227,811 | 4,539,310 | 1,070,395 | 1,040,808
Adjustment to Non-PEO NEO Compensation Footnote | Deductions from, and additions to, total compensation in the Summary Compensation Table by year to calculate CAP are shown in the tables below. The amounts reflected for fiscal year 2023 have been revised from the amounts previously reported in last year’s Proxy Statement to reflect the correct Average Summary Compensation Table Total for our Non-PEO NEOs and to incorporate an inadvertent omission of certain tranches of outstanding stock option awards granted in a previous year that remained outstanding as of the end of fiscal year 2023.
|  | Average CAP to Non-PEO NEOs |
|  | 2024 |  |  | 2023 |  |  | 2022 |  |  | 2021 |  |  | 2020 |
|  | $ |  |  | $ |  |  | $ |  |  | $ |  |  | $ |
Summary Compensation Table Total |  |  | 2,983,724 |  |  |  | 2,493,824 |  |  |  | 958,883 |  |  |  | 1,441,564 |  |  |  | 928,500 |
Adjustments for Stock and Option Awards |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment for grant date fair values in the Summary Compensation Table |  |  | (2,053,545 | ) |  |  | (1,738,234 | ) |  |  | (328,662 | ) |  |  | (977,265 | ) |  |  | (405,485 | )
Year-end fair value of unvested awards granted in the covered fiscal year |  |  | 1,079,261 |  |  |  | 1,822,445 |  |  |  | 1,915,468 |  |  |  | 318,056 |  |  |  | 469,469 |
Year-over-year difference of year-end fair values for unvested awards granted in prior years that remained outstanding at the covered fiscal year end |  |  | (371,623 | ) |  |  | 372,583 |  |  |  | 1,344,256 |  |  |  | (16,871 | ) |  |  | 9,332 |
Fair values at vest date for awards granted and vested in covered fiscal year |  |  | 188,739 |  |  |  | 93,271 |  |  |  | 296,601 |  |  |  | 145,504 |  |  |  | 87,658 |
Difference in fair values between prior year-end fair values and vest date fair values for awards granted in prior years and vesting in the covered fiscal year |  |  | 571,594 |  |  |  | 183,922 |  |  |  | 352,765 |  |  |  | 159,408 |  |  |  | (48,666 | )
Compensation Actually Paid (as calculated) |  |  | 2,398,150 |  |  |  | 3,227,811 |  |  |  | 4,539,310 |  |  |  | 1,070,395 |  |  |  | 1,040,808 |
Compensation Actually Paid vs. Total Shareholder Return |  |  |  |  |
Compensation Actually Paid vs. Net Income |  |  |  |  |
Compensation Actually Paid vs. Company Selected Measure |  |  |  |  |
Total Shareholder Return Vs Peer Group |  |  |  |  |
Tabular List, Table | Tabular List of Financial Performance Measures As described in greater detail in the CD&A, we have a significant focus on pay-for-performance. The most important financial and non-financial performance measures used to link CAP (as calculated in accordance with the SEC rules) to our NEOs in 2024 to our performance were:
• |  | Revenue target of $370M;
• |  | Scaling TransMedics Aviation to a minimum of 16 planes by September 30, 2024;
• |  | Initiation of a US Lung clinical program/trial by December 31, 2024;
• |  | Completion of ERP upgrade and HRIS implementation by December 31, 2024;
• |  | PMA submission of 2 new assembly improvements for current OCS modules by December 31, 2024;
• |  | Sustained EBITDA positive for a minimum of 2 quarters in 2024;
• |  | FDA submission of new OCS boards with integrated lactate and ABG sensors by December 31, 2024;
• |  | Complete development of OCS Connect II & OCS Cloud Connectivity by December 31, 2024; and
• |  | Supply chain to control management of all inventory at NOP hubs by December 31, 2024.
Total Shareholder Return Amount | $ 327.99 | 415.2 | 324.67 | 100.79 | 104.68
Peer Group Total Shareholder Return Amount | 105.42 | 106.34 | 99.81 | 125.43 | 130.04
Net Income (Loss) | $ 35,500,000 | $ (25,000,000) | $ (36,200,000) | $ (44,200,000) | $ (28,700,000)
Company Selected Measure Amount | 441,500,000 | 241,600,000 | 93,500,000 | 30,300,000 | 25,600,000
PEO Name | Waleed H. Hassanein, M.D. | Waleed H. Hassanein, M.D. | Waleed H. Hassanein, M.D. | Waleed H. Hassanein, M.D. | Waleed H. Hassanein, M.D.
Measure:: 1 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Revenue target of $370M |  |  |  |
Measure:: 2 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Scaling TransMedics Aviation to a minimum of 16 planes by September 30, 2024 |  |  |  |
Measure:: 3 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Initiation of a US Lung clinical program/trial by December 31, 2024 |  |  |  |
Measure:: 4 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Completion of ERP upgrade and HRIS implementation by December 31, 2024 |  |  |  |
Measure:: 5 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | PMA submission of 2 new assembly improvements for current OCS modules by December 31, 2024 |  |  |  |
Measure:: 6 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Sustained EBITDA positive for a minimum of 2 quarters in 2024 |  |  |  |
Measure:: 7 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | FDA submission of new OCS boards with integrated lactate and ABG sensors by December 31, 2024 |  |  |  |
Measure:: 8 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Complete development of OCS Connect II & OCS Cloud Connectivity by December 31, 2024 |  |  |  |
Measure:: 9 |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Name | Supply chain to control management of all inventory at NOP hubs by December 31, 2024 |  |  |  |
PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | $ (6,096,424) | $ (4,940,574) | $ (1,825,900) | $ (6,377,940) | $ (1,445,960)
PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 3,958,387 | 5,365,601 | 10,641,357 | 2,075,714 | 1,671,287
PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (2,382,164) | 3,440,246 | 8,789,191 | (136,012) | 67,306
PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 971,689 | 532,735 | 1,647,831 | 949,688 | 312,077
PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 4,976,159 | 1,684,536 | 2,680,973 | 1,291,136 | (325,501)
Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (2,053,545) | (1,738,234) | (328,662) | (977,265) | (405,485)
Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 1,079,261 | 1,822,445 | 1,915,468 | 318,056 | 469,469
Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | (371,623) | 372,583 | 1,344,256 | (16,871) | 9,332
Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | 188,739 | 93,271 | 296,601 | 145,504 | 87,658
Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year |  |  |  |  |
Pay vs Performance Disclosure |  |  |  |  |
Adjustment to Compensation, Amount | $ 571,594 | $ 183,922 | $ 352,765 | $ 159,408 | $ (48,666)

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iii + Details
Name: | ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph ii + Details
Name: | ecd_CompActuallyPaidVsNetIncomeTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i + Details
Name: | ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_MeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupIssuersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupTotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 6 + Details
Name: | ecd_TabularListTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnVsPeerGroupTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4 Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7 Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ecd_MeasureAxis=1
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=2
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=3
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=4
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=5
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=6
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=7
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=8
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_MeasureAxis=9
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_PeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |